Trial · NCT02098538
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT02098538, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2025-09-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma. Trials, record NCT02098538. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02098538
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- NCT number
- NCT02098538
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 38 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Regorafenib
- First posted
- 2014-03-28
- Last updated
- 2025-09-10
- Results first posted
- 2025-09-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Alive With and Without Disease Progression | 6 months | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Primary | Best Overall Response Rate | 6 months | (BOR = CR+PR) documented by RECIST v1.1 criteria |
| Secondary | Number of Participants Evaluated for Adverse Events | 1 year | Safety will be assessed in terms of AEs, laboratory data and vital sign data, which will be collected for all patients. Appropriate summaries of these data will be presented. AE will be listed individually per patient according to CTCAE version 4.0, and the number of patients experiencing each AE will be summarized. The safety population will comprise all patients who receive at least one dose of study treatment. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Alive With and Without Disease Progression | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Best Overall Response Rate | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Evaluated for Adverse Events | 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Alive With and Without Disease Progression | Patients With Adenoid Cystic Carcinoma | Participants alive without disease progression | 4 | Participants | |
| Number of Participants Alive With and Without Disease Progression | Patients With Adenoid Cystic Carcinoma | Participants alive with disease progression | 6 | Participants | |
| Number of Participants Alive With and Without Disease Progression | Patients With Adenoid Cystic Carcinoma | Not evaluable | 28 | Participants | |
| Best Overall Response Rate | Patients With Adenoid Cystic Carcinoma | Participants with CR+PR | 1 | Participants | |
| Best Overall Response Rate | Patients With Adenoid Cystic Carcinoma | Participants without CR+PR | 37 | Participants | |
| Number of Participants Evaluated for Adverse Events | Patients With Adenoid Cystic Carcinoma | 38 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Patients With Adenoid Cystic Carcinoma | 38 | |
| Overall Study | COMPLETED | Patients With Adenoid Cystic Carcinoma | 38 | |
| Overall Study | NOT COMPLETED | Patients With Adenoid Cystic Carcinoma | 0 |
Source ClinicalTrials.gov
Adverse events164
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase, increased | Investigations | Patients With Adenoid Cystic Carcinoma | 27 | 38 | |
| other | Aspartate aminotransferase, increased | Investigations | Patients With Adenoid Cystic Carcinoma | 29 | 38 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Patients With Adenoid Cystic Carcinoma | 14 | 38 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Patients With Adenoid Cystic Carcinoma | 8 | 38 | |
| other | Alkaline phosphatase, increased | Investigations | Patients With Adenoid Cystic Carcinoma | 25 | 38 | |
| other | Anorexia | Metabolism and nutrition disorders | Patients With Adenoid Cystic Carcinoma | 13 | 38 | |
| other | Anal ulcer | Gastrointestinal disorders | Patients With Adenoid Cystic Carcinoma | 1 | 38 | |
| other | Anal hemorrhage | Gastrointestinal disorders | Patients With Adenoid Cystic Carcinoma | 1 | 38 | |
| other | Anxiety | Psychiatric disorders | Patients With Adenoid Cystic Carcinoma | 2 | 38 | |
| other | Anemia | Blood and lymphatic system disorders | Patients With Adenoid Cystic Carcinoma | 18 | 38 |
1 to 10 of 164Source ClinicalTrials.gov
See all 164 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Patients With Adenoid Cystic Carcinoma | 28 | 38 |
| Total, other adverse events | Patients With Adenoid Cystic Carcinoma | 38 | 38 |
| Total, serious adverse events | Patients With Adenoid Cystic Carcinoma | 14 | 38 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02098538
GET https://conductscience.org/api/trials/v1/NCT02098538/events?page=2